Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Comparison of adverse drug reactions among four COVID-19 vaccines in Europe using the EudraVigilance database: Thrombosis at unusual sites

Maria Abbattista1 | Ida Martinelli1 | Flora Peyvandi1,2

1Fondazione IRCCS Ca’ Granda–Ospedale Maggiore Policlinico, UOC Medicina Generale, A. Bianchi Bonomi Hemophilia and Thrombosis Center, Milan, Italy
2Università degli Studi di Milano, Department of Pathophysiology and Transplantation, Milan, Italy

Correspondence Flora Peyvandi, Fondazione IRCCS Ca’Granda Ospedale Maggiore Policlinico, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Via Pace 9, 20122 Milan, Italy. Email: flora.peyvandi@unimi.it

Abstract

Background: Real-world experience with adenoviral vector vaccines against COVID-19 raised some safety concerns. Cases of cerebral vein thrombosis (CVT) associated with thrombocytopenia have been observed after the first dose of the adenoviral vector vaccines CHADOX1 NCOV-19 and AD26.COV2.S.

Objectives: To assess the reporting rate of CVT as adverse drug reaction (ADR) for the COVID-19 vaccines authorized in Europe.

Patients and Methods: This observational study assessed the CVT reporting rate attributed to four COVID-19 vaccines authorized in Europe, namely Tozinameran (Pfizer-Biontech), CX-024414 (Moderna), CHADOX1 NCOV-19 (AstraZeneca), and AD26.COV2.S (Janssen). Data on thrombotic ADRs reported on EudraVigilance database between January 1, 2021 and July 30, 2021, were collected. ADRs referring to CVT were identified. The reporting rate of CVT was expressed as 1 million individual vaccinated-days with 95% confidence interval. Finally, an observed-to-expected (OE) analysis was performed.

Results: The reporting rate of CVT per 1 million person vaccinated-days was 1.92 (95% confidence interval [CI], 1.71–2.12) for Tozinameran, 5.63 (95% CI, 4.74–6.64) for CX-024414, 21.60 (95% CI, 20.16–23.11) for CHADOX1 NCOV-19, and 11.48 (95% CI, 9.57–13.67) for AD26.COV2.S. CVT occurred alongside thrombocytopenia for the four vaccines. The OE ratio was greater than one for all four vaccines, both with the lowest and the highest CVT background incidence.

Conclusions: This report on EudraVigilance data strengthens anecdotal findings on CVT following COVID-19 vaccinations. Although the European Medicines Agency released an alert only for CHADOX1 NCOV-19 and AD26.COV2.S, Tozinameran and CX-024414 also are complicated by CVT, albeit to lesser extent.

Keywords adverse drug reaction, cerebral vein thrombosis, COVID-19, thrombocytopenia, vaccine
BACKGROUND

The current pandemic of coronavirus disease (COVID-19) caused by severe acute respiratory syndrome coronavirus (SARS-CoV-2) stimulated rapid vaccine production against the disease. The European Medicines Agency (EMA) has approved so far four COVID-19 vaccines, namely the mRNA Tozinameran (Pfizer-Biontech), the mRNA CX-024414 (Moderna), chimpanzee adenoviral vector CHADOX1 NCOV-19 (AstraZeneca), and adenoviral vector type 26 AD26.COV2.S (Janssen). Although no major warnings emerged from the authorization trials, post-marketing real-world experience raised safety concerns. A few cases of rare thrombotic manifestations such as cerebral vein thrombosis (CVT) were observed, alongside thrombocytopenia, mainly after the first dose of the CHADOX1 NCOV-19 and AD26.COV2.S vaccines. An immune response, similar to heparin-induced thrombocytopenia, has been suggested as a possible explanation for the association between thrombotic events and low platelet count. This syndrome, called vaccine-induced immune thrombocytopenia, is characterized by the development of high-titer antibodies to platelet factor 4-polyanion complexes despite no heparin exposure. Recently, EMA finalized two signal evaluations on the adenoviral vector vaccines CHADOX1 NCOV-19 and AD26.COV2.S, with blood clots and thrombocytopenia listed as very rare side effects. The aim of this study was to assess, using the EudraVigilance database, the reporting rate of CVT among the thrombotic adverse drug reactions (ADRs) attributed to the four COVID-19 vaccines authorized by EMA.

METHODS

The EudraVigilance is a public pharmacovigilance database, available at www.adrreports.eu, that allows managing and analyzing the ADRs, thus enabling post-marketing surveillance in Europe. We collected ADRs (access date July 30, 2021) for Tozinameran, CX-024414, CHADOX1 NCOV-19, and AD26.COV2.S. Individual case safety reports (ICSRs) submitted from all the European Member States from January 1, 2021 to July 30, 2021 (210 days) were exported to an internal database. ADRs related to thrombotic events were selected from the total using the following filtering conditions: (1) Reported suspected reaction contains “thrombosis”; (2) Gateway date “01/01/2021–30/07/2021.” Cases were reviewed and CVT defined if at least one among “cerebral thrombosis,” “cerebral venous/vein thrombosis,” “cerebral venous sinus thrombosis,” “jugular vein thrombosis,” or “sagittal/transverse sinus thrombosis” was present in the reaction list. Splanchnic vein thrombosis (SVT) was attributed if at least one among “splanchnic/splenic vein thrombosis,” “portal vein thrombosis,” “mesenteric vein thrombosis,” or “portosplenicomesenteric venous thrombosis” was listed. In addition, multiple unusual sites were determined if CVT, SVT, and/or terms such as “renal/ovarian/retinal/subclavian vein thrombosis” were reported together in the same ICSR. Otherwise, reports containing at least “thrombosis” among suspected reactions were considered as “common sites,” either arterial or venous. Thrombocytopenia was declared with “thrombocytopenia,” “low platelet count,” or “platelet count decreased” listed among suspected reactions.

The reporting rate of CVT during the study period was estimated using the following formula: number of thrombotic ADRs reported in the study period divided by the number of individuals who received their first dose of vaccine in the same period, 1 Jan 2021–30 Jul 2021 (retrieved from the European Center for Disease Prevention and Control, ECDC, public database available at https://www.ecdc.europa.eu/en/publications-data/data-covid-19-vaccination-eueea). Each estimate was expressed as 1 million individual vaccinated-days with the respective 95% confidence interval (CI). An observed-to-expected (OE) analysis within 28 days post first vaccine dose was also performed, considering the estimated lowest CVT background incidence rates and the highest CVT background incidence rates of 0.2 and 1.5 per 100,000 person-years, respectively. The person-time at risk was calculated as number of first doses x 28/365.2425 x 1/100,000. The OE ratio was expressed as standardized morbidity ratio (SMR) with 95% CI.

RESULTS AND DISCUSSION

We identified for each vaccine the total number of ADRs reported in the study period and selected those related to thrombotic events, from now on “thrombotic ADRs.” For Tozinameran we identified 2926 thrombotic ADRs out of 311,364 total ADRs (0.9%), for CX-024414 1878 out of 80,428 (2.3%), for CHADOX1 NCOV-19 4752 out of 337,712 (1.4%), and for AD26.COV2.S 761 out of 18,744 (4.1%). Table 1 shows the distribution of thrombotic ADRs according to the age group and sex. Overall, the age group <65 was more prevalent among the thrombotic ADRs of adenoviral vector vaccines than among those of mRNA vaccines and the prevalence of female sex was approximately 55% for the four vaccines. CVT events were observed for all vaccines, a lower reporting rate of unusual site thrombosis ADRs was observed for the mRNA compared to the adenoviral vaccines (Table 2). CVT events alongside with thrombocytopenia have been reported for all vaccines, ranging from 3–5% to 31–44% for mRNA and adenoviral vaccines, respectively.
The number of individuals in Europe who received the first dose in the study period was 183,288,011 (Tozinameran), 25,038,569 (CX-024414), 38,664,988 (CHADOX1 NCOV-19), and 10,972,234 (AD26.COV2.S). The reporting rate of CVT per 1 million individual vaccinated-days in the study period was 1.92 (95% CI, 1.72–2.13) for Tozinameran, 5.63 (95% CI, 4.74–6.64) for CX-024414, 21.60 (95% CI, 20.16–23.11) for CHADOX1 NCOV-19, and 11.48 (95% CI, 9.57–13.67) for AD26.COV2.S. In Table 3 the OE analysis showed SMR greater than one for all four vaccines, both with the lowest and the highest known background incidence, suggesting an excess of risk. However, when the highest background incidence was considered, the SMR was lower for both the mRNA vaccines than for adenoviral vector ones.

This study employed the EudraVigilance data to evaluate the reporting rate of CVT after COVID-19 vaccination, with the goal to provide a comprehensive look at thrombotic complications with the available vaccines. Rare thromboses at unusual sites, with or without thrombocytopenia, have been reported in EudraVigilance for the four vaccines, even though thrombocytopenia appeared to be more prevalent in patients who developed thrombosis after the adenoviral vector vaccines. Moreover, a higher prevalence of CVT was observed in the <65 years old group for adenoviral vector vaccines than for the others. However, this observation should be interpreted cautiously considering the different target populations who did benefit from each vaccine. Adenoviral vaccines have been mostly used in the young and AD26.COV2.S was only recently introduced, so we cannot exclude that the observed different reporting rates are due to a selection bias. Moreover, the reporting rate of CVT for AD26.COV2.S was likely to be affected by the low number of individuals who did benefit from this vaccine.

Concerning the extent of the CVT disease burden, CVT incidence increased in the general population over the past decade, from 2–5 to 13.2–15.7 annual cases per million, owing to growing awareness and improved imaging techniques. Moreover, these figures are likely to be underestimated because of lack of dedicated epidemiological studies and variability of ethnic groups with different degree of exposure to infectious diseases, well-known triggers of CVT. Additionally, the reporting rate of CVT could not be directly compared to the incidence rate in the general population, these being different measures that use different definitions of the time at risk. Therefore, whether the incidence of CVT is higher in vaccinated people than in the general population is beyond the scope of this study. However, the OE analysis showed an SMR greater than one suggesting an excess of risk for all four vaccines, but particularly for the adenoviral vector ones considering the highest background incidence rate. These data should be critically interpreted because they are based on several assumptions and we do not know the exact background incidence rates, which could widely differ among the vaccine target populations. In addition, a possible underestimation of the ADRs’ registration should be considered.

This study has the typical limitations of a study based upon pharmacovigilance data. First, the possibility of underreporting should
be mentioned. The incidence of CVT for each vaccine could not be estimated lacking information on the extent of underreporting and exact time of occurrence. Only a minority of data are missing for sex and age group, but other strong thrombotic risk factors are not available (e.g., oral contraceptive use, thrombophilia abnormalities). Therefore, no causal inference should be done from these data due

- TABLE 2 Frequency of thrombocytopenia, younger age group, sex, and fatality among thrombotic adverse drug reactions in common sites, cerebral vein thrombosis and splanchnic vein thrombosis

| Characteristics | Common sites | CVT | SVT | Multiple unusual sites | Thrombotic events | N, (%) |
|-----------------|--------------|-----|-----|------------------------|-------------------|--------|
| COVID−19 mRNA vaccine Tozinameran | Thrombocytopenia | 41 (2) | 19 (5) | 13 (13) | 1 (100) | 2926 |
| No. of cases <65Y | 1037 (42) | 175 (50) | 59 (57) | 0 |
| No. of female | 1305 (53) | 207 (59) | 44 (42) | 1 (100) |
| Fatal | 81 (3) | 29 (8) | 12 (12) | 1 (100) |
| Tot No. of events | 2470 (84%) | 351 (12%) | 104 (3.5%) | 1 (0.03%) |
| | 0.8% | 0.1% | 0.03% | 0.0003% | 0.9% |
| COVID−19 mRNA vaccine CX−024414 | Thrombocytopenia | 19 (1) | 4 (3) | 0 | 0 | 1878 |
| No. of cases <65Y | 897 (53) | 82 (58) | 38 (67) | 2 (100) |
| No. of female | 911 (54) | 70 (50) | 30 (53) | 1 (50) |
| Fatal | 72 (4) | 11 (8) | 4 (7) | 0 |
| Tot No. of events | 1678 (89%) | 141 (8%) | 57 (3%) | 2 (0.1%) |
| | 2% | 0.2% | 0.07% | 0.002% | 2.3% |
| COVID−19 vaccine CHADOX1 NCOV−19 | Thrombocytopenia | 338 (9) | 370 (44) | 93 (40) | 37 (84) | 4752 |
| No. of cases <65Y | 1931 (53) | 608 (65) | 159 (69) | 39 (89) |
| No. of female | 1852 (51) | 519 (62) | 122 (53) | 31 (70) |
| Fatal | 128 (4) | 148 (18) | 28 (12) | 12 (27) |
| Tot No. of events | 3642 (77%) | 835 (18%) | 231 (5%) | 44 (1%) |
| | 1% | 0.2% | 0.07% | 0.01% | 1.4% |
| COVID−19 vaccine AD26.COV2.S | Thrombocytopenia | 40 (7) | 39 (31) | 15 (58) | 7 (100) | 761 |
| No. of cases <65Y | 423 (70) | 97 (77) | 22 (85) | 5 (71) |
| No. of female | 297 (49) | 93 (74) | 14 (54) | 5 (71) |
| Fatal | 13 (2) | 16 (13) | 1 (4) | 2 (29) |
| Tot No. of events | 602 (79%) | 126 (17%) | 26 (3%) | 7 (1%) |
| | 3% | 0.7% | 0.1% | 0.04% | 4.1% |

Abbreviations: ADRs, adverse drug reactions; CVT, cerebral vein thrombosis; SVT, splanchnic vein thrombosis.

- TABLE 3 Observed-to-expected analysis

| Vaccine name | Person-time at risk (100,000 person-years) | Lowest highest background incidence | Expected CVT | Observed CVT | SMR (95% CI) |
|--------------|-------------------------------------------|------------------------------------|--------------|--------------|--------------|
| COVID−19 mRNA vaccine Tozinameran | 140.51 | 0.2 | 28.10 | 351 | 12.49 (11.23–13.85) |
| | | 1.5 | 210.77 | | 1.67 (1.57–1.78) |
| COVID−19 mRNA COVID−19 mRNA vaccine CX−024414 | 19.19 | 0.2 | 36.73 (33.17–40.60) | 31.59 | 4.9 (4.42–5.41) |
| | | 1.5 | 38.73 | 31.59 | 5.5 (5.01–6.08) |
| COVID−19 vaccine CHADOX1 NCOV−19 | 29.64 | 0.2 | 140.85 (135.07–146.77) | 140.85 | 18.78 (18.02–19.58) |
| | | 1.5 | 140.85 | | 18.78 (18.02–19.58) |
| COVID−19 vaccine AD26.COV2.S | 8.41 | 0.2 | 74.9 (63.35–83.42) | | 18.78 (18.02–19.58) |
| | | 1.5 | 12.62 | 9.99 (8.97–11.10) | 9.99 (8.97–11.10) |

Abbreviations: CI, confidence interval; CVT, cerebral vein thrombosis; SMR, standardized morbidity ratio.
to missing information on possible confounders. Moreover, we fail to provide reporting rates standardized for age and countries due to missing data. Considering that the safety profile of a vaccine may differ within each target population (i.e., higher risks in the youngest age groups), comparison between different reporting rates for age categories or countries should be avoided, because they will include many biases and lack of appropriateness. In addition, we lacked information for performing a stratified OE analysis.

In conclusion, although EMA released an alert only for adenoviral vector vaccines (CHADOX1 NCOV-19 and AD26.COV2.S), mRNA vaccines (Tozinameran and CX-024414) also are complicated by CVT, albeit to a lesser extent. In accordance with the EMA statements, the benefits of vaccination against COVID-19 continue to outweigh the risks of side effects, including rare life-threatening thrombotic manifestations that appear to occur with all four vaccines but with many differences in frequency and mechanism that need further investigation. Therefore, we prompt more awareness on the pivotal role of pharmacovigilance, especially for those events that remain unnoticed during the clinical trials and urge spontaneous reports.

ACKNOWLEDGMENT
Open Access Funding provided by Universita degli Studi di Milano within the CRUI-CARE Agreement. [Correction added on 11 May 2023, after first online publication: CRUI-CARE funding statement has been added.]

CONFLICTS OF INTEREST
F.P. has received honoraria for participating as a speaker at satellite symposia organized by Roche, Sanofi, Sobi, and Takeda; and is a member of advisory boards of Roche, Sanofi, Sobi, and Takeda. I.M. reports personal and non-financial support from Bayer, Roche, Rovi, and Novo Nordisk outside of the submitted work. M.A. has nothing to disclose.

AUTHOR CONTRIBUTIONS
All authors had full access to all study data and take responsibility for their integrity and for the accuracy of the data analysis. M.A. acquired, analyzed, and interpreted the data, and drafted the manuscript. I.M. interpreted the data and critically revised the manuscript. F.P. conceived the study, interpreted the data, and critically revised the manuscript. F.P. and I.M. supervised the study.

ORCID
Maria Abbattista  https://orcid.org/0000-0003-3620-3347

Ida Martinelli  https://orcid.org/0000-0001-9218-3622
Flora Peyvandi  https://orcid.org/0000-0001-7423-9864

REFERENCES
1. Wolf ME, Luz B, Niehaus L, Bhogal P, Bäzner H, Henkes H. Thrombocytopenia and intracranial venous sinus thrombosis after “COVID-19 Vaccine AstraZeneca” exposure. J Clin Med. 2021;10(8):1599. doi:https://doi.org/10.3390/jcm10081599
2. Schultz NH, Servoll IH, Michelsen AE, et al. Thrombosis and thrombocytopenia after ChAdOx1 nCoV-19 vaccination. N Engl J Med. 2021;384(22):2124-2130. doi:https://doi.org/10.1056/nejma2104882
3. See I, Su JR, Lale A, et al. US case reports of cerebral venous sinus thrombosis with thrombocytopenia after Ad26.COV2.S vaccination, March 2 to April 21, 2021. JAMA. 2021;325(24):1-9. doi:https://doi.org/10.1001/jama.2021.7517
4. Greinacher A, Thiele T, Warlentin TE, Weisser K, Kyrlie PA, Eichinger S. Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination. N Engl J Med. 2021;384(22):2092-2101. doi:http://dx.doi.org/10.1056/nejmoa2104840
5. AstraZeneca’s COVID-19 vaccine: EMA finds possible link to very rare cases of unusual blood clots with low blood platelets. https://www.ema.europa.eu/en/news/astrazenecas-covid-19-vaccine-ema-finds-possible-link-very-rare-cases-unusual-blood-clots-low-blood. Accessed May, 2021.
6. COVID-19 Vaccine Janssen: EMA finds possible link to very rare cases of unusual blood clots with low blood platelets. https://www.ema.europa.eu/en/news/covid-19-vaccine-janssen-ema-finds-possible-link-very-rare-cases-unusual-blood-clots-low-blood. Accessed May, 2021.
7. Coutinho JM, Zuurbier SM, Aramideh M, Stam J. The Incidence of Cerebral Venous Thrombosis. Stroke. 2012;43(12):3375–3377. doi:http://dx.doi.org/10.1161/strokeaha.112.671453
8. Devasagayam S, Wyatt B, Leyden J, Kleinig T. Cerebral Venous Sinus Thrombosis Incidence Is Higher Than Previously Thought. Stroke. 2016;47(9):2180–2182. doi:http://dx.doi.org/10.1161/strokeaha.116.013617
9. Mahaux O, Bauchau V, Van Holle L. Pharmacoepidemiological considerations in observed-to-expected analyses for vaccines. Pharmacoepidemiol Drug Saf. 2016;25(2):215-222. doi:http://doi.org/10.1002/pds.3918

How to cite this article: Abbattista M, Martinelli I, Peyvandi F. Comparison of adverse drug reactions among four COVID-19 vaccines in Europe using the EudraVigilance database: Thrombosis at unusual sites. J Thromb Haemost. 2021;19:2554–2558. https://doi.org/10.1111/jth.15493